Autologous Transplantation of P63+Lung Progenitor Cells for Chronic Obstructive Pulmonary Disease Therapy: An Open-label, Controlled, First-in-Human Trial

被引：0

作者：

Zhang, T. ^{[1
]}

Wang, Y. ^{[2
]}

Zhou, Y. ^{[1
]}

Zhao, Y. ^{[2
]}

Zuo, W. ^{[2
]}

机构：

[1] Regend Therapeut, Shanghai, Peoples R China

[2] Tongji Univ, Stem Cell Ctr, Shanghai, Peoples R China

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A1221

引用

页数：2

共 50 条

[21] Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study
Su-yun Li
Jian-sheng Li
Ming-hang Wang
Yang Xie
Xue-qing Yu
Zi-kai Sun
Li-jun Ma
Wei Zhang
Hai-long Zhang
Fan Cao
Ying-chao Pan
BMC Complementary and Alternative Medicine, 12
[22] Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Ailawadhi, Sikander
Chen, Zi
Huang, Bo
Paulus, Aneel
Collins, Mary C.
Fu, Lei
Li, Mingyu
Ahmad, Mohammad
Men, Lichuang
Wang, Hengbang
Davids, Matthew S.
Liang, Eric
Mekala, Divya J.
He, Zhicong
Lasica, Masa
Yannakou, Costas K.
Parrondo, Ricardo
Glass, Laura
Yang, Dajun
Chanan-Khan, Asher
Zhai, Yifan
CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2385 - 2393
[23] AN OPEN-LABEL, PHASE I TRIAL OF TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS
Koseki, M.
Yamashita, S.
ATHEROSCLEROSIS, 2015, 241 (01) : E111 - E111
[24] Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial
Eklof, Josefin
Alispahic, Imane Achir
Sivapalan, Pradeesh
Wilcke, Torgny
Seersholm, Niels
Armbruster, Karin
Kjaergaard, Jakob Lyngby
Saeed, Mohamad Isam
Nielsen, Thyge Lynghoj
Browatzki, Andrea
Overgaard, Rikke Holmen
Fenlev, Camilla Sund
Harboe, Zitta Barella
Andreassen, Helle Frost
Lapperre, Therese Sophie
Pedersen, Lars
Johnsen, Stine
Ulrik, Charlotte Suppli
Janner, Julie
Moberg, Mia
Heidemann, Maria
Weinreich, Ulla Moller
Vijdea, Roxana
Linde, Hans
Titlestad, Ingrid
Johansson, Sofie Lock
Rosenvinge, Flemming Schonning
Ostergaard, Christian
Ghathian, Khaled Saoud Ali
Gundersen, Lise
Christensen, Christina Wellendorph
Bangsborg, Jette
Jensen, Torben Tranborg
Sorensen, Vibeke Muff
Ellingsgaard, Thilde
Datcu, Raluca
Coia, John Eugenio
Bodtger, Uffe
Jensen, Jens Ulrik Staehr
TRIALS, 2022, 23 (01)
[25] Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial
Josefin Eklöf
Imane Achir Alispahic
Pradeesh Sivapalan
Torgny Wilcke
Niels Seersholm
Karin Armbruster
Jakob Lyngby Kjærgaard
Mohamad Isam Saeed
Thyge Lynghøj Nielsen
Andrea Browatzki
Rikke Holmen Overgaard
Camilla Sund Fenlev
Zitta Barella Harboe
Helle Frost Andreassen
Therese Sophie Lapperre
Lars Pedersen
Stine Johnsen
Charlotte Suppli Ulrik
Julie Janner
Mia Moberg
Maria Heidemann
Ulla Møller Weinreich
Roxana Vijdea
Hans Linde
Ingrid Titlestad
Sofie Lock Johansson
Flemming Schønning Rosenvinge
Christian Østergaard
Khaled Saoud Ali Ghathian
Lise Gundersen
Christina Wellendorph Christensen
Jette Bangsborg
Torben Tranborg Jensen
Vibeke Muff Sørensen
Thilde Ellingsgaard
Raluca Datcu
John Eugenio Coia
Uffe Bodtger
Jens Ulrik Stæhr Jensen
Trials, 23
[26] CANaspire, a First-in-Human Phase 1/2 Controlled Open-Label Study of BBP-812, a Recombinant AAV9-hASPA Vector for the Treatment of Canavan Disease
Eichler, F.
Laforet, G.
Andonian, H.
Kinane, B.
Kirby, K.
Nagy, A.
Shaywitz, A.
Balser, J.
Bley, A.
ANNALS OF NEUROLOGY, 2022, 92 : S184 - S185
[27] Incidence of Chronic Obstructive Pulmonary Disease Symptom-Defined Exacerbations: Exploratory Analysis from a Long-Term Open-Label Active-Controlled Safety Trial of Nebulized Glycopyrrolate/eFlow® CS
Kerwin, E. M.
Ganapathy, V.
Murray, L.
Rajagopalan, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[28] The GuardOne clinical trial: a first in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease
Ridha, E.
Jones, J. J.
Abrahamsen, I.
Golipour, A.
Pfeifer, R.
Khan, A.
Mason, C.
Escolar, D.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A80 - A80
[29] Design and rationale for an open-label, randomized, controlled pilot trial to evaluate the changes in blood uremic toxins in patients with chronic kidney disease by dietary therapy with sake lees
Toshiaki Tokumaru
Tadashi Toyama
Yusuke Nakade
Hisayuki Ogura
Megumi Oshima
Shiori Nakagawa
Motoe Furuichi
Shinji Kitajima
Norihiko Sakai
Miho Shimizu
Yasunori Iwata
Takashi Wada
Clinical and Experimental Nephrology, 2024, 28 : 440 - 446
[30] Design and rationale for an open-label, randomized, controlled pilot trial to evaluate the changes in blood uremic toxins in patients with chronic kidney disease by dietary therapy with sake lees
Tokumaru, Toshiaki
Toyama, Tadashi
Nakade, Yusuke
Ogura, Hisayuki
Oshima, Megumi
Nakagawa, Shiori
Furuichi, Motoe
Kitajima, Shinji
Sakai, Norihiko
Shimizu, Miho
Iwata, Yasunori
Wada, Takashi
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (05) : 440 - 446

← 1 2 3 4 5 →